Bringing our guidance together by topic

We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.

We expect that this will help increase the use of promising medicines and treatments in the NHS. This will lead to a more effective use of NHS resources, and better outcomes for patients.

Currently we produce guidance products separately. For example, as technology appraisals (TAs) and guidelines.

Starting in 2024, we’ve begun to incorporate our published technology appraisals guidance into our guidelines. So, you'll be able to access all our guidance on a topic in one place.

This will mean: 

  • It’s easier for commissioners, practitioners and patients to access and decide on treatment options. 
  • Better adoption of promising new treatments across the NHS. 
  • It’s easier to achieve the best outcomes for patients whilst making the best use of NHS resources. 

Getting this right is vital to ensuring that patients can access the most clinically-effective treatments, that offer the best value to the taxpayer. 

How we're doing this

To start with, we’re working through our published technology appraisals and presenting them, unchanged, within the relevant NICE guideline.

We’ve already incorporated over 180 technology appraisals into guidelines in this way. Our aim is to incorporate around another 200 technology appraisals into our guidelines before the end of March 2026, in line with our commitment in the 2024 voluntary scheme for branded medicines pricing, access and growth.

In some cases however, we cannot easily incorporate technology appraisals into our guidelines. For example:

  • When the existing NICE guideline pathway is inconsistent with technology appraisal recommendations or where the evidence underpinning the guideline may have changed.
  • Where existing treatment recommendations have become outdated as evidence, cost-effectiveness or clinical practice have changed.
  • When the patient population eligible to receive a treatment needs to be expanded beyond the original technology appraisal recommendation, to align with new evidence and best practice.

In these cases, a more in-depth approach is needed to make sure we can update our recommendations if necessary, in order to produce usable guidance that reflects changes in the care pathway.

We cannot do this alone. We’re part of a complex system and it’s essential that we engage with our stakeholders and work together with them collaboratively to develop our methods and approaches in this area.

To support this, we’ve established the bringing NICE guidance together stakeholder panel to help us consider what methods and processes we’ll need to keep our guidance up-to-date across our portfolio of products, as we bring it all together.

Next steps

About the bringing NICE guidance together stakeholder panel

The bringing NICE guidance together stakeholder panel is chaired by NICE’s chief scientific officer and includes staff from relevant stakeholder organisations including the NHS, patient groups, the life sciences industry, Royal Colleges, academia and NICE teams. Other individuals are invited to join for specific agenda items or co-opted onto the group as and when required. This includes, for example, individuals with specific expertise or interest in specific clinical topics. 

A broad range of relevant interest groups and perspectives are represented on the panel. They are working collaboratively with us, sharing knowledge, reviewing problem statements and helping find workable options and solutions where technology appraisals cannot currently be easily presented in a NICE guideline. 

The panel began meeting regularly in April 2025. 

We will regularly update this page, with more details on the topics and issues the panel are working on.